 |
Welcome
- Bill Louv, PhD, President; Project Data Sphere
- Julia Beaver, MD, Chief of Medical Oncology, Oncology Center of Excellence; US Food and Drug Administration
|
 |
Keynote: Rare cancer registries – Impact on clinical practice, drug development and regulators
- David Fajgenbaum, MD, MBA, MSc, FCPP, Assistant Professor of Medicine, Translational Medicine & Human Genetics; University of Pennsylvania
|
 |
Panel 1: How do rare cancer registries impact clinical decision making?
Moderator: Dave Reese, MD, Executive Vice President of Research & Development; Amgen, Inc.
- David Miller, MD, Medical Oncologist; Massachusetts General Hospital
- Gregory Reaman, MD, Associate Director, Pediatric Oncology, Oncology Center of Excellence; US Food and Drug Administration
- Ting Yu, MD, MS, Medical Director; EMD Serono, a business of Merck KGaA, Darmstadt Germany
|
 |
Panel 2: How do rare cancer registries advance drugs in development?
Moderator: Zhen Su, MD, MBA, Senior Vice President, Head of US & Global Oncology Franchise; EMD Serono, a business of Merck KGaA, Darmstadt Germany
- Martha Donoghue, MD, Pediatric Solid Tumors Scientific Liaison; US Food and Drug Administration
- Gregory Friberg, MD, Vice President Global Development, Therapeutic Area Head Heme/Onc & Bone; Amgen, Inc.
- Michael Wong, MD, PhD, FRCPC, Professor, Department of Melanoma Medical Oncology, Division of Cancer Medicine; The University of Texas MD Anderson Cancer Center
|
 |
Fireside Chat: Generating clinical evidence for biomarker-driven indications
- Sean Khozin, MD, MPH, Vice President, Global Head of Data Strategy; Janssen Research & Development, LLC, to interview Josh Bilenker, MD, Chief Executive Officer; Loxo Oncology, Inc.
|
 |
Call to Action & Next Steps
- Andy Crighton, MD, Chief Executive Officer; CEO Roundtable on Cancer and Project Data Sphere
|
 |
FULL EVENT REPLAY
|
